Evaluation of Coffee Therapy for Improvement of Renal Oxygenation

Status Completed

Clinical Trial Summary

Over 1.25 million Americans have Type 1 Diabetes (T1D), increasing risk for early death from cardiovascular disease (CVD). Despite advances in glycemic and blood pressure control, a child diagnosed with T1D is expected to live up to 17 years less than non-diabetic peers. The strongest risk factor for CVD and mortality in T1D is diabetic kidney disease (DKD). Current treatments, such as control of hyperglycemia and hypertension, are beneficial, but only partially protect against DKD. This limited progress may relate to a narrow focus on clinical manifestations of disease, rather than on the initial metabolic derangements underlying the initiation of DKD. Renal hypoxia, stemming from a potential metabolic mismatch between increased renal energy expenditure and impaired substrate utilization, is increasingly proposed as a unifying early pathway in the development of DKD. T1D is impacted by several mechanisms which increase renal adenosine triphosphate (ATP) consumption and decrease ATP generation. Caffeine, a methylxanthine, is known to alter kidney function by several mechanisms including natriuresis, hemodynamics and renin-angiotensin-aldosterone system. In contrast, to other natriuretic agents, caffeine is thought to fully inhibit the local tubuloglomerular feedback (TGF) response to increased distal sodium delivery. This observation has broad-ranging implications as caffeine can reduce renal oxygen (O2) consumption without impairing effective renal plasma flow (ERPF) and glomerular filtration rate (GFR). There are also data suggesting that chemicals in coffee besides caffeine may provide important cardio-renal protection. Yet, there are no data examining the impact of coffee-induced natriuresis on intrarenal hemodynamic function and renal energetics in youth-onset T1D. Our overarching hypothesis in the proposed pilot and feasibility trial is that coffee drinking improves renal oxygenation by reducing renal O2 consumption without impairing GFR and ERPF. To address these hypotheses, we will measure GFR, ERPF, renal perfusion and oxygenation in response to 7 days of cold brew coffee (one Starbucks® Cold brew 325ml bottle daily [205mg caffeine]) in an open-label pilot and feasibility trial in 10 adolescents with T1D already enrolled in the CASPER Study (PI: Bjornstad).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03878277
Study type	Interventional
Source	University of Colorado, Denver
Contact
Status	Completed
Phase	Phase 2
Start date	July 1, 2019
Completion date	September 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03886974` - Transition to Adult Care in Type 1 Diabetes
Completed	`NCT05620251` - Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes
Completed	`NCT03623113` - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes	N/A
Active, not recruiting	`NCT05078658` - Low-carbohydrate Diet in Children With Type 1 Diabetes	N/A
Not yet recruiting	`NCT06018324` - CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
Withdrawn	`NCT03736083` - Introducing CGM at Type 1 Diabetes Diagnosis	N/A
Completed	`NCT03177096` - Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes	N/A
Not yet recruiting	`NCT06418269` - The Effect of Therapeutic Play on Anxiety and Fear Levels in Children With Diabetes	N/A
Completed	`NCT04172077` - Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes
Recruiting	`NCT04950634` - Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
Completed	`NCT04450745` - Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients	N/A
Completed	`NCT03165786` - A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes	N/A
Terminated	`NCT04028960` - IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase	Phase 2
Recruiting	`NCT05324488` - Diabetes Registry Graz for Biomarker Research
Completed	`NCT02984709` - Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes	N/A
Completed	`NCT02984514` - Brown Adipose Tissue in Type 1 Diabetes	N/A
Recruiting	`NCT06372392` - Universal Fixed Meal Boluses Usage in Patients With Medtronic Minimed 780G Pumps	N/A
Recruiting	`NCT03311516` - New Insulin Therapy by Multiwave Bolus	N/A
Recruiting	`NCT05973799` - Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes	N/A
Completed	`NCT03711656` - Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of Coffee Therapy for Improvement of Renal Oxygenation — COFFEE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms